By Michelle Calhoun
By all accounts, the current biologics development pipeline is healthy and R&D investment continues to drive growth in novel antibody development. Near-term forecasts indicate a growth rate so robust that it may continue to outpace contract manufacturing capacity. Contributing further is pressure to supply chains to address the increasing requirements for complex molecules such as antibody drug conjugates (ADCs) and bispecific antibodies. This article will explore both market drivers.
Recent trends reported by Future Market Insights (FMI) support the notion that:
- Over the past few years, biotech patent applications have increased an average of 23 percent annually.
- More than 1,500 biomolecules are currently undergoing clinical trials, and because the biomolecule success rate is twice that of small molecule therapies, that momentum continues to build.
- From 2003 to 2017, FDA-approved recombinant therapeutics development increased about 400 percent resulting in record approvals in this area year over year.